What We're Reading: Government Wants Clinical Trial Findings More Widely Available
What we're reading, September 19, 2016: the government update rules on reporting clinical trial findings; hospitals say they aren't receiving discounts for Valeant's heart drugs; and the FDA approved the first treatment for Duchenne muscular dystrophy.
Universities and institutions that do not comply with new policies to make findings from clinical trials more widely available could find they are losing out on funding.
Valeant Pharmaceuticals said it would give discounts to hospitals for 2 heart drugs, but some hospitals say they haven’t seen a reduction in cost for these expensive treatments. Hospitals have reported a number of issues including not knowing to negotiate for the discounts instead of receiving them automatically,
The FDA has approved the first drug to treat Duchenne muscular dystrophy. The agency overruled medical staffers who earlier this year questioned the effectiveness of the drug,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025